Direkt zum Inhalt
Merck
  • Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.

Virology (2021-03-12)
Kaustuv Nayak, Kamalvishnu Gottimukkala, Sanjeev Kumar, Elluri Seetharami Reddy, Venkata Viswanadh Edara, Robert Kauffman, Katharine Floyd, Grace Mantus, Deepali Savargaonkar, Pawan Kumar Goel, Satyam Arora, Manju Rahi, Carl W Davis, Susanne Linderman, Jens Wrammert, Mehul S Suthar, Rafi Ahmed, Amit Sharma, Kaja Murali-Krishna, Anmol Chandele
ZUSAMMENFASSUNG

India is one of the most affected countries by COVID-19 pandemic; but little is understood regarding immune responses to SARS-CoV-2 in this region. Herein we examined SARS-CoV-2 neutralizing antibodies, IgG, IgM, IgA and memory B cells in COVID-19 recovered individual from India. While a vast majority of COVID-19 recovered individuals showed SARS-CoV-2 RBD-specific IgG, IgA and IgM antibodies (38/42, 90.47%; 21/42, 50%; 33/42, 78.57% respectively), only half of them had appreciable neutralizing antibody titers. RBD-specific IgG, but not IgA or IgM titers, correlated with neutralizing antibody titers and RBD-specific memory B cell frequencies. These findings have timely significance for identifying potential donors for plasma therapy using RBD-specific IgG assays as surrogate measurement for neutralizing antibodies in India. Further, this study provides useful information needed for designing large-scale studies towards understanding of inter-individual variation in immune memory to SARS CoV-2 natural infection for future vaccine evaluation and implementation efforts.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
o-Phenylendiamin -dihydrochlorid, tablet, 4 mg substrate per tablet